Fig. 6.
Multi-omics-based identification of potential therapeutic targets for gliomas. (A) CEACAM1 CNV (Log-Rank P-value = 0.00118). (B) DLL3 gene expression (Log-Rank P-value = 6.23e-06). (C) IDH1,chr2:209113112–209113112,+,Missense_Mutation,SNP,CC > CT (Log-Rank P-value = 0.0475). (D) IGFBP2 protein expression (Log-Rank P-value = 0.00181). (E) MAP3K1 methylation (Log-Rank P-value = 4.14e-05). (F) MIR22 miRNA expression (Log-Rank P-value = 0.0047).